[go: up one dir, main page]

ZA969087B - Farnesyl transferase inhibiting 2-quinolone derivatives. - Google Patents

Farnesyl transferase inhibiting 2-quinolone derivatives.

Info

Publication number
ZA969087B
ZA969087B ZA9609087A ZA969087A ZA969087B ZA 969087 B ZA969087 B ZA 969087B ZA 9609087 A ZA9609087 A ZA 9609087A ZA 969087 A ZA969087 A ZA 969087A ZA 969087 B ZA969087 B ZA 969087B
Authority
ZA
South Africa
Prior art keywords
farnesyl transferase
quinolone derivatives
transferase inhibiting
inhibiting
quinolone
Prior art date
Application number
ZA9609087A
Other languages
English (en)
Inventor
David William End
Marc Gaston Venet
Patrick Rene Angibaud
Gerard Charles Sanz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA969087B publication Critical patent/ZA969087B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9609087A 1995-10-31 1996-10-29 Farnesyl transferase inhibiting 2-quinolone derivatives. ZA969087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31

Publications (1)

Publication Number Publication Date
ZA969087B true ZA969087B (en) 1998-04-29

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609087A ZA969087B (en) 1995-10-31 1996-10-29 Farnesyl transferase inhibiting 2-quinolone derivatives.

Country Status (28)

Country Link
US (1) US5968952A (xx)
EP (2) EP1106610B1 (xx)
JP (1) JP4257869B2 (xx)
KR (1) KR100417620B1 (xx)
CN (1) CN1101391C (xx)
AR (1) AR004699A1 (xx)
AT (2) ATE269322T1 (xx)
AU (1) AU712435B2 (xx)
CA (1) CA2231143C (xx)
CY (1) CY2287B1 (xx)
CZ (1) CZ290954B6 (xx)
DE (2) DE69618999T2 (xx)
DK (1) DK1019395T3 (xx)
EA (1) EA000719B1 (xx)
ES (2) ES2171736T3 (xx)
HU (1) HU224032B1 (xx)
IL (1) IL123567A (xx)
MY (1) MY116577A (xx)
NO (1) NO314037B1 (xx)
NZ (1) NZ321576A (xx)
PL (1) PL184168B1 (xx)
PT (1) PT1019395E (xx)
SI (1) SI1019395T1 (xx)
SK (1) SK282642B6 (xx)
TR (1) TR199800720T2 (xx)
TW (1) TW349948B (xx)
WO (1) WO1997016443A1 (xx)
ZA (1) ZA969087B (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290992C (en) 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
ES2224462T3 (es) 1997-12-11 2005-03-01 Janssen Pharmaceutica N.V. Anilidas mimeticas del acido retinoico.
JP2002518387A (ja) * 1998-06-16 2002-06-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
KR100591603B1 (ko) * 1998-07-06 2006-06-20 얀센 파마슈티카 엔.브이. 생체내 방사선 감작성을 갖는 파네실 단백질 트랜스퍼라제억제제
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
JP3495706B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6458800B1 (en) 1998-12-23 2002-10-01 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
BR0008202A (pt) * 1999-02-11 2002-02-19 Pfizer Prod Inc Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
EP1267929A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
EP1261374A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525244A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
EP1267872A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030125326A1 (en) * 2000-02-29 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525234A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064195A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525238A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001246478A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7067531B2 (en) * 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7173040B2 (en) * 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
US20040044032A1 (en) * 2000-11-28 2004-03-04 End David William Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
BR0116302A (pt) 2000-12-19 2004-01-13 Pfizer Prod Inc Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
BRPI0208075B8 (pt) 2001-03-12 2021-05-25 Janssen Pharmaceutica Nv processo para a preparação de compostos de imidazol
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) * 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
NZ588432A (en) * 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
PL1815247T3 (pl) 2004-11-05 2013-08-30 Janssen Pharmaceutica Nv Terapeutyczne zastosowanie inhibitorów transferazy farnezylowej i metody kontroli ich skuteczności
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
US7414050B2 (en) 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
BRPI0812450A2 (pt) 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CA2794112A1 (en) 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011282614B2 (en) 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
JP2013536241A (ja) * 2010-08-24 2013-09-19 ブリガム・ヤング・ユニバーシティ 抗転移化合物
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2013052465A1 (en) * 2011-10-02 2013-04-11 Trustees Of Boston University [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3133066A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
PT3534885T (pt) 2016-11-03 2021-04-13 Kura Oncology Inc Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
DK0677513T3 (da) * 1994-04-15 2000-03-27 Takeda Chemical Industries Ltd Octahydro-2-naphthalencarboxylsyrederivat, dets fremstilling og anvendelse

Also Published As

Publication number Publication date
DK1019395T3 (da) 2002-05-06
DE69632751T2 (de) 2005-08-04
AU7493396A (en) 1997-05-22
ATE269322T1 (de) 2004-07-15
MX9802067A (es) 1998-08-30
HUP9802424A2 (hu) 1999-10-28
HUP9802424A3 (en) 2003-02-28
MY116577A (en) 2004-02-28
AU712435B2 (en) 1999-11-04
EP1106610B1 (en) 2004-06-16
DE69632751D1 (de) 2004-07-22
ES2171736T3 (es) 2002-09-16
TR199800720T2 (xx) 1998-09-21
EP1106610A1 (en) 2001-06-13
CZ127298A3 (cs) 1998-12-16
CY2287B1 (en) 2003-07-04
JP4257869B2 (ja) 2009-04-22
HK1027576A1 (en) 2001-01-19
CZ290954B6 (cs) 2002-11-13
NO980928D0 (no) 1998-03-04
KR100417620B1 (ko) 2004-05-27
EA000719B1 (ru) 2000-02-28
DE69618999T2 (de) 2002-09-26
PL328230A1 (en) 1999-01-18
CA2231143C (en) 2005-06-21
CN1101391C (zh) 2003-02-12
SK282642B6 (sk) 2002-10-08
ATE212627T1 (de) 2002-02-15
CN1200732A (zh) 1998-12-02
WO1997016443A1 (en) 1997-05-09
NO980928L (no) 1998-04-29
PL184168B1 (pl) 2002-09-30
DE69618999D1 (de) 2002-03-14
JPH11514635A (ja) 1999-12-14
US5968952A (en) 1999-10-19
CA2231143A1 (en) 1997-05-09
IL123567A0 (en) 1998-10-30
SI1019395T1 (en) 2002-06-30
KR19990063639A (ko) 1999-07-26
ES2233557T3 (es) 2005-06-16
AR004699A1 (es) 1999-03-10
IL123567A (en) 2002-11-10
EP1019395A1 (en) 2000-07-19
TW349948B (en) 1999-01-11
SK55698A3 (en) 1999-02-11
HU224032B1 (hu) 2005-05-30
NO314037B1 (no) 2003-01-20
EP1019395B1 (en) 2002-01-30
EA199800395A1 (ru) 1998-10-29
HK1036064A1 (en) 2001-12-21
NZ321576A (en) 1999-05-28
PT1019395E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
ZA969087B (en) Farnesyl transferase inhibiting 2-quinolone derivatives.
ZA9610254B (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives.
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
DE69604588D1 (en) 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren
ZA961444B (en) Pyrazolylbenzoyl derivatives.
GB2306473A8 (en) Glucoxide derivatives
ZA961449B (en) Isoxazolylbenzoyl derivatives.
CY2380B1 (en) Pde IV inhibiting 2-cyanoiminoimidazole derivatives.
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA985211B (en) Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
IL130453A0 (en) Farnesyl transferase inhibitors
ZA962821B (en) 4-indolylpiperazinyl derivatives.
GB9524976D0 (en) Subsea clamp
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA964034B (en) N-aminopyridone derivatives.
GB9510563D0 (en) Well inhibition
IL155594A0 (en) Farnesyl transferase inhibitors
ZA971254B (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors
IL141626A0 (en) Farnesyl transferase inhibitors
GB2307940B (en) Subsea clamp
ZA965748B (en) Benzo(g)quinoline derivatives.
GB9610174D0 (en) Prenyl transferase inhibitors
ZA964870B (en) Rapamycin derivatives.